Report: FDA lists 106 adverse events for Abbott's rapid COVID-19 test; none for other rapid tests - MassDevice
Abbott’s ID Now test machine (Image from Abbott)

Users of the ABT) ID Now point-of-care diagnostic test for COVID-19 have reported 106 false-negative or otherwise incorrect or inadequate results to the FDA since April — and none for other companies’ rapid diagnostics for the novel coronavirus, according to a report by Kaiser Health News.

That’s up from the 15 adverse event reports the agency reported it had received by May 14, when it issued a warning about the test’s accuracy.  The FDA granted the ID Now test an emergency use ization (EUA) on March 27, and by mid-May said it was investigating whether the false-negative results could be due to the types of swabs used or the type of viral transport media. A preliminary study report by National Public Radio.

Abbott has said that the NYU study results are not consistent with other studies — some with sensitivity performance in the 80th percentile and other studies with sensitivity at or above 90%. One study listed the test’s sensitivity at 94%, the company noted. In a guidance released May 11, the FDA said it considers a 95% accuracy rate for diagnostic tests acceptable.

Abbott began advising customers in mid-April that ID Now is a rapid test that was not designed for use with viral transport media. The company also recommended using dry nasal swabs to collect samples. The 106 reported adverse events took place between April 5 to  April 27, 2020.

An FDA spokesperson told Kaiser Health News that the agency had not received adverse event reports for any other COVID-19 rapid diagnostic test. The news agency also reported that an FDA official said in May that tests conducted outside of a laboratory might still be useful even if they miss one in five positive cases.

President Trump has touted the ID Now as the test used every day in the White House. Kaiser Health News cited contract records that showed the Executive Office of the President has spent roughly $140,000 on Abbott test kits.

The Abbott Park, Ill.-based company said that it has delivered 3.7 million tests to all 50 states with a complaint rate of 0.017% for false negative results, which it has shared with the FDA.

“COVID-19 testing should not be politicized or sensationalized, but rather scientifically assessed as a part of a broad set of countermeasures to protect public health,” Abbott spokesperson Darcy Ross said in an email to MassDevice. “We strive to be as close to perfection as is scientifically possible, and we are reassured by what we’ve seen in the field. We’ve seen accuracy rates in the mid-90s in some studies, including our own, which is incredible when you consider how far we’ve come in only a matter of a few months. This point-of-care device is helping save lives as a part of complex testing regimen that includes additional laboratory testing for patients that require it. Its accessibility and reliability are critical, and we agree with the experts who see the tremendous value it is providing.”





RSS From Medical Design & Outsourcing

  • BREAKING: Johnson & Johnson finally unveils its new robot-assisted surgery system
    Johnson & Johnson (NYSE:JNJ) today shared details on its surgical robotic platform that it says offers unrivaled flexibility and control compared to the rest of the market. The new system is designed with six arms to provide more control and flexibility in surgery, while its arms will be integrated into the operating table. Additionally, the platform… […]
  • B. Braun halts certain Aesculap knee implants
    B. Braun is notifying customers who purchased certain Aesculap knee systems to temporarily cease implanting them while the company addresses a “possible malfunction.” In a Nov. 16 letter sent to customers worldwide, the company said a “locally accumulated number of aseptic loosenings have been reported to us in connection with the univation X system. ln the… […]
  • Key steps for medical device manufacturers effective CAPA management
    By Sarah Fitzgerald and Stewart Eisenhart, Emergo Group Ensuring adequate processes for corrective and preventative action (CAPA) management is a critical step for medical device manufacturers implementing ISO 13485:2016 or other quality management systems. However, effective CAPA management can prove a perennial challenge even to larger, more mature manufacturers. Get the full story here at… […]
  • Depleted hospital capital accounts require medtechs to be`flexible’
    As hospitals battle another surge in COVID-19, medical device companies have to worry about more than temporary reductions in elective surgeries. Hospitals struggling to account for every dollar are beginning to push for different ways to select and pay for new medical technology, particularly large capital items like robotic surgery systems, according to a review… […]
  • Explorer says AR, AI will improve surgeon-sales rep connections
    Explorer Surgical, one of several companies working to established remote connections between surgeons and advisors located outside the operating room, introduced a suite of audio/video functionality that it says will established “unprecedented” levels of communications. The Chicago-based startup says its platform will include augmented reality. According to a release, the HIPAA-compliant system will allow proxies,… […]
  • Medline converts Ga. plant to manufacture masks
    Medline announced today that it will repurpose part of a Georgia factory to produce medical face masks, beginning in January 2021. The Northfield, Ill.-based company said it is modifying its Lithia Springs, Ga., plant to begin its first North American face mask production, and anticipates launching a second production line launching later in 2021. When… […]
  • Diversified Plastics names engineering manager
    Diversified Plastics announced today that it has appointed Vincent Pope as engineering manager. Pope has nearly 30 years of experience serving in leadership positions in a range of industries, including 13 years in plastic-injection molding, plus computer, electronics, additive manufacturing and contract manufacturing. Prior to joining Minneapolis-based Diversified Plastics, Pope was president & CEO of… […]
  • Forécreu has a new logo
    Forécreu — maker of hollow bars for the medical device market — has unveiled a new logo meant to feature a simple, bold, modern look. The “O” in the logo represents the single-hole cannulated stock used in surgical instruments and implants. It also includes a new tagline: Building Critical Partnerships. “This new tagline captures the… […]
  • The 10 largest medical device companies in the world
    Even as the world’s largest medical device companies grapple with COVID-19 and the resulting recession, they’re doing important work to help humanity manage the crisis. Read on to find out more about the 10 largest companies in the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medical device… […]
  • Brooklyn spending $500K on BioBAT research and manufacturing space
    SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Brooklyn Borough President Eric Adams awarded the grant to SUNY to construct a state-of-the-art biotechnology research and manufacturing space at BioBAT, a nonprofit organization seeking to grow the biotechnology industry in New York City.… […]
  • Tissium wins FDA IDE for vascular sealant
    Tissium today said it received FDA investigational device exemption for its vascular sealant. The vascular sealant is designed to quickly achieve hemostasis and prevent post-operative bleeding after peripheral vascular surgeries. It also offers biocompatibility with a simple preparation and application process for surgeons. Tissium’s vascular sealant polymer complements sutures as a sealant for a fully… […]